2021

PetHonesty has received a majority investment from Vestar Capital Partners

Founded in 2018 and based in Austin, Texas, PetHonesty is a trusted leader in pet health, providing premium pet supplements that are formulated to help address a range of common pet ailments, including mobility, digestion and allergies, providing a healthy supplement to traditional pet diets. Currently, PetHonesty products are available through multiple e-commerce platforms, including Amazon, Chewy and the company’s proprietary website.

Ben Arneberg, Chief Executive Officer and Co-founder of PetHonesty, commented, “The Lincoln team was instrumental in facilitating a successful transaction for all stakeholders and assisting us in finding the right partner to help PetHonesty execute our growth strategy. We are excited to partner with Vestar Capital Partners and start the next chapter of our story.”

Lincoln acted as the exclusive financial advisor to PetHonesty, working closely with the management team and shareholders throughout the sale process. The Lincoln team provided valuable industry expertise and managed all aspects of the process, including the preparatory, marketing, negotiation and due diligence phases of the transaction.

PetHonesty’s management team and employees invested alongside Vestar Capital Partners in the transaction. The terms of the transaction were not disclosed.

This transaction marks Lincoln International’s eighth pet / animal health deal in the last nine months and continues the firm’s impressive track record of working with owner-entrepreneurs.

PetHonesty VCP Capital 2021 Connect with a Senior Team Member
Lincoln’s in-depth pet industry expertise and knowledge combined with a highly dedicated team of bankers proved critical in achieving a successful outcome.
Ben Arneberg
Chief Executive Officer and Co-founder of PetHonesty

Meet our Senior Team

Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.